Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Rating of "Buy" by Analysts

Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) have received a consensus rating of "Buy" from the seven brokerages that are presently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued a report on the stock in the last year is $15.25.

Several analysts have weighed in on the company. Leerink Partners reaffirmed an "outperform" rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Canaccord Genuity Group reissued a "buy" rating and set a $16.00 price objective on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Piper Sandler restated an "overweight" rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Finally, HC Wainwright reiterated a "buy" rating and issued a $18.00 price target on shares of Tenaya Therapeutics in a research note on Friday, October 18th.

Tenaya Therapeutics Trading Up 4.6 %

Shares of TNYA stock traded up $0.09 during trading hours on Wednesday, reaching $2.05. The company's stock had a trading volume of 433,878 shares, compared to its average volume of 466,693. The stock has a market capitalization of $161.72 million, a P/E ratio of -1.32 and a beta of 2.35. The firm's fifty day simple moving average is $2.13 and its 200 day simple moving average is $3.14. Tenaya Therapeutics has a one year low of $1.61 and a one year high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.06. As a group, equities research analysts forecast that Tenaya Therapeutics will post -1.52 earnings per share for the current fiscal year.

Insider Transactions at Tenaya Therapeutics

In related news, CEO Faraz Ali sold 9,748 shares of the company's stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $2.89, for a total value of $28,171.72. Following the transaction, the chief executive officer now owns 188,331 shares in the company, valued at $544,276.59. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 19,539 shares of company stock valued at $56,468. Insiders own 32.76% of the company's stock.

Institutional Investors Weigh In On Tenaya Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Tenaya Therapeutics by 16.4% during the 1st quarter. Vanguard Group Inc. now owns 2,862,916 shares of the company's stock valued at $14,973,000 after purchasing an additional 403,472 shares during the last quarter. American Century Companies Inc. boosted its position in shares of Tenaya Therapeutics by 27.7% during the second quarter. American Century Companies Inc. now owns 102,114 shares of the company's stock valued at $317,000 after buying an additional 22,146 shares during the last quarter. Integral Health Asset Management LLC boosted its position in shares of Tenaya Therapeutics by 3.3% during the second quarter. Integral Health Asset Management LLC now owns 2,325,000 shares of the company's stock valued at $7,208,000 after buying an additional 75,000 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Tenaya Therapeutics by 42.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 102,026 shares of the company's stock worth $316,000 after buying an additional 30,446 shares in the last quarter. Finally, Algert Global LLC purchased a new position in Tenaya Therapeutics in the 2nd quarter worth about $74,000. Institutional investors own 90.54% of the company's stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.